Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Majalah Farmaseutik Jurnal Farmasi Indonesia
Tri Murti Andayani
Gadjah Mada University
Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
COST - MINIMIZATION ANALYSIS KAPTOPRIL DIBANDINGKAN LISINOPRIL PADA PASIEN HIPERTENSI RAWAT JALAN Diesty Anita Nugraheni; Tri Murti Andayani
Jurnal Farmasi Indonesia Vol 12 No 2 (2015): Jurnal Farmasi Indonesia
Publisher : Fakultas Farmasi Universitas Setia Budi

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (146.83 KB) | DOI: 10.31001/jfi.v12i2.91

Abstract

Cost minimal of hypertension can saving money because cardiovascular morbidity and mortality. This study intend to know cost minimal among captopril versus lisinopril of outpatients with hypertension, based on hospital aspect. This study was epidemiology survey, with descriptive analysis and retrospective. The subject was outpatients hypertension in RSUP Dr. Sardjito and RS PKU Muhammadiyah Yogyakarta using captopril or lisinopril as new therapy, addition therapy, or replacement therapy, observed in two months therapy. Samples were selected non-randomly with purpose. Number of samples are 50 patients. The cost was direct medical cost of outpatients with hypertension. The analysis of data describe the use of antihypertensive, sum of direct medical cost, and cost-minimization analysis. The results showed that the clinical outcome of captopril and lisinopril was equivalent. The mean direct medical cost in hypentension without compelling indications for captopril was Rp 134.715,41, and lisinopril was Rp 315.093,16. In hypentension with compelling indications diabetes mellitus, mean direct medical cost for captopril was Rp 242.430 and lisinopril was Rp 492.270. Captopril was cost minimal among two diagnosis.
Analisis Biaya Penyakit Diabetes Retinopati di Rumah Sakit Aulia Nadya Rizki Imansari; Tri Murti Andayani; Dwi Endarti
Majalah Farmaseutik Vol 17, No 1 (2021)
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/farmaseutik.v17i1.47745

Abstract

Diabetes retinopati merupakan komplikasi mikrovaskuler diabetes melitus yang ditandai dengan kerusakan dan sumbatan pembuluh darah retina yang menjadi penyebab kebutaan. Penyakit ini membutuhkan rentang waktu pengobatan yang panjang sehingga membutuhkan biaya yang besar. Penelitian ini bertujuan untuk gambaran biaya penyakit diabetes retinopati dan mengetahui faktor – faktor yang mempengaruhi biaya penyakit. Jenis penelitian ini adalah analitik observasional dengan rancangan cross sectional study, pengambilan data dilakukan secara retrospektif. Biaya yang diperhitungkan adalah biaya medik langsung berdasarkan perspektif rumah sakit. Subjek penelitian ini adalah pasien diabetes retinopati rawat jalan periode November 2018 – Januari 2019 di rumah sakit mata Yogyakarta. Kriteria inklusi penelitian ini adalah pasien diabetes melitus tipe 2 dengan komplikasi diabetes retinopati yang menjalani terapi rawat jalan, memiliki kelengkapan data rekam medis dan kelengkapan rincian pembiayaan rumah sakit. Hasil penelitian diperoleh 60 pasien yang memenuhi kriteria inklusi. Total biaya penyakit diabetes retinopati sebesar Rp 112.710.950 per 3 bulan rawat jalan. Rata-rata biaya per pasien Rp 1.878.516 ± Rp 1.954.213. Komponen biaya terbesar adalah biaya pelayanan non operatif berupa tindakan fotokoagulasi laser. Faktor frekuensi kunjungan, jenis terapi, lama menderita diabetes retinopati berpengaruh terhadap biaya penyakit (p<0,05).
Cost Effectiveness Analysis (CEA) Strategi Terapi Anemia pada Pasien Penyakit Ginjal Kronis Nurfina Dian Kartikawati; Tri Murti Andayani; Dwi Endarti
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 12, No 3
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jmpf.72614

Abstract

Chronic kidney disease (CKD) is a condition in which the kidneys are unable to maintain a fluid balance of metabolic waste that is progressive, irreversible, and takes place slowly. Anemia is a complication of CKD that contributes to morbidity, mortality, and quality of life of patients, as well as greater costs of care. This study aims to evaluate the differences in the effectiveness and cost of anemia therapy with epoetin in patients with chronic kidney disease. The study was conducted in an analytical-observational manner with a retrospective cohort design from the provider's perspective. The sample used was CKD patients with anemia who met the inclusion criteria for the period January - December 2020, data were taken from medical records and patient financial recapitulation. Statistical analysis was carried out on the effectiveness of anemia therapy with epoetin based on the achievement of clinical outcomes of increasing Hb values within 3 months and financing calculated based on direct medical costs. A total of 113 patients met the inclusion criteria, consisting of 96 patients in the epoetin alpha group and 17 patients in the epoetin beta group. The percentage of achieving therapeutic targets in the epoetin beta group was higher (11.76%) than in the epoetin alfa group (10.42%). The average increase in Hb in the EPO beta group was higher than in the EPO alpha group. The cost of epoetin for anemia treatment in the beta epoetin group (Rp 1,005,365) was lower than the epoetin alfa group (Rp 1,017,188). The ICER value obtained was IDR -125,966, indicating a cost savings of IDR 125,966 to increase 1% of the achievement of therapeutic targets for Hb values >10 g/dl. The cost of therapy with EPO beta is lower than EPO alpha and the achievement of Hb therapy targets is better in EPO beta than EPO alpha.
Co-Authors Diesty Anita Nugraheni Imansari, Aulia Nadya Rizki Nurfina Dian Kartikawati